Zimmer Biomet (ZBH) announced U.S. FDA 510(k) clearance for the OsseoFit Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural humeral (upper shoulder bone) anatomy1-3 to optimize anatomical fit while maximizing preservation of healthy bone. The OsseoFit Stemless Shoulder System expands the company’s expansive total shoulder portfolio and integrates with Identity Humeral Heads with Versa-Dial Technology for infinite offset placement as well as the Alliance Glenoid for a broad range of glenoid options to adapt to a patient’s unique anatomy.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target lowered to $118 from $125 at Barclays
- Citi opens ‘positive catalyst watch’ on Zimmer Biomet
- Zimmer announces FDA clearance of Persona SoluTion Porous Plasma Spray Femur
- Zimmer Biomet assumed with an Equal Weight at Morgan Stanley
- Zimmer Biomet receives FDA approval for Oxford Cementless Partial Knee
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
